G protein-coupled receptor accessory proteins and signaling: Pharmacogenomic insights

Methods in Molecular Biology

Volumn 1175, Issue , 2014, Pages 121-152

  Thompson, Miles D ^a   Cole, David E C ^a   Jose, Pedro A ^a   Chidiac, Peter ^a  

^a NONE

Author keywords

Accessory proteins; Activator of G protein signaling (AGS); G protein coupled receptor; G protein coupled receptor kinases (GRK); Hypertension; Pharmacogenomics; Regulator of G protein signaling (RGS); Signaling

Indexed keywords

ACCESSORY PROTEIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 4; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN; RGS PROTEIN; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR KINASE;

ARTICLE; DNA POLYMORPHISM; GENE DISRUPTION; HUMAN; HYPERTENSION; LIGAND BINDING; MONOGENIC DISORDER; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHARMACOGENETICS; SIGNAL TRANSDUCTION;

ANIMALS; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; HYPERTENSION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84927630842     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0956-8_7     Document Type: Article

References (207)

1. Spiegel AM, Weinstein LS (2004) Inherited diseases involving g proteins and G proteincoupled receptors. Annu Rev Med 55:27-39
2. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639-650
3. Thompson MD, Cole DE, Jose P (2008) The pharmacogenomics of G protein-coupled receptor signaling. Methods Mol Biol 448:77-108
4. Libert F, Vassart G, Parmentier M (1991) Current developments in G-protein-coupled receptors. Curr Opin Cell Biol 3:218-223
5. Civelli O, Reinscheid RK, Zhang Y et al (2013) G protein-coupled receptor deorphanizations. Annu Rev Pharmacol Toxicol 53:127-146
6. Thompson MD, Capra V, Takasaki J et al (2007) A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate. Pharmacogenet Genomics 17:539-549
7. Liu X, Davis D, Segaloff DL (1993) Disruption of potential sites for N-linked glycosylation does not impair hormone binding to the lutropin?choriogonadotropin receptor if Asn-173 is left intact. J Biol Chem 268:1513-1516
8. Karpa KD, Lidow MS, Pickering MT et al (1999) N-linked glycosylation is required for plasma membrane localization of D5, but not D1, dopamine receptors in transfected mammalian cells. Mol Pharmacol 56:1071-1078
9. Karnik SS, Ridge KD, Bhattacharya S et al (1993) Palmitoylation of bovine opsin and its cysteine mutants in COS cells. Proc Natl Acad Sci U S A 90:40-44
10. Ovchinnikov Y, Abdulaev N, Bogachuk A (1988) Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated. FEBS Lett 230:1-5
11. Unger VM, Hargrave PA, Baldwin JM et al (1997) Arrangement of rhodopsin transmembrane alpha-helices. Nature 389:203-206
12. Palczewski K, Kumasaka T, Hori T et al (2000) Crystal structure of rhodopsin: a G proteincoupled receptor. Science 289:739-745
13. Dohlman HG, Thorner J, Caron MG et al (1991) Model systems for the study of seventransmembrane-segment receptors. Annu Rev Biochem 60:653-688
14. Hibert MF, Trumpp-Kallmeyer S, Hofl ack J et al (1993) This is not a G protein-coupled receptor. Trends Pharmacol Sci 14:7-12
15. Strader CD, Fong TM, Tota MR et al (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132
16. Rana BK, Shiina T, Insel PA (2001) Genetic variations and polymorphisms of G proteincoupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol 41:593-624
17. Thompson MD, Siminovitch KA, Cole DE (2008) G Protein-coupled receptor pharmacogenetics. Methods Mol Biol 448:139-185
18. Neves SR, Iyengar R (2002) Modeling of signaling networks. Bioessays 24:1110-1117
19. Lynch KR, O’Neill GP, Liu QY et al (1999) Characterization of the human cysteinyl leukotriene CysLT(1) receptor. Nature 399: 789-793
20. Heise CE, O’Dowd BF, Figueroa DJ et al (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536
21. Figueroa DJ, Breyer RM, Defoe SK et al (2001) Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 163:226-233
22. Mellor EA, Frank N, Soler D et al (2003) Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci U S A 100:11589-11593
23. Sjostrom M, Johansson AS, Schroder O et al (2003) Dominant expression of the CysLT(2) receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 23:E37-E41
24. Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7
25. Gomes I, Jordan BA, Gupta A et al (2001) G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med 79:226-242
26. AbdAlla S, Lother H, Quitterer U (2000) AT(1)-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98
27. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U (2004) Factor XIIIA transglutaminase crosslinks AT(1) receptor dimers of monocytes at the onset of atherosclerosis. Cell 119:343-354
28. Zeng FY, Wess J (1999) Identifi cation and molecular characterization of m3 muscarinic receptor dimers. J Biol Chem 274: 19487-19497
29. George SR, Lee SP, Varghese G et al (1998) A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 273:30244-30248
30. Lee SP, O’Dowd BF, Rajaram RD et al (2003) D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42:11023-11031
31. Romano C, Yang WL, O’Malley KL (1996) Metabotropic glutamate receptor 5 is a disulfi de-linked dimer. J Biol Chem 271: 28612-28616
32. Karnik SS, Sakmar TP, Chen HB et al (1988) Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc Natl Acad Sci U S A 85:8459-8463
33. Savarese TM, Wang CD, Fraser CM (1992) Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. J Biol Chem 267:11439-11448
34. Zhang P, Johnson PS, Zollner C et al (1999) Mutation of human mu opioid receptor extracellular “disulfi de cysteine” residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res Mol Brain Res 72:195-204
35. Capra V, Thompson MD, Cole DE et al (2007) Cysteinyl-leukotrienes and their receptors in health and disease. Med Res Rev 27:469-527
36. Thompson MD, Takasaki J, Capra V et al (2006) G protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective. Mol Diagn Ther 10:353-366
37. Thompson MD, Comings DE, Abu-Ghazalah R et al (2004) Variants of the orexin2/hcrt2 receptor gene identifi ed in patients with excessive daytime sleepiness and patients with Tourette’s syndrome comorbidity. Am J Med Genet B Neuropsychiatr Genet 129B:69-75
38. Thompson MD, Burnham WM, Cole DEC (2005) The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci 42:311-392
39. Gainetdinov RR, Premont RT, Bohn LM et al (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144
40. Weinstein LS, Chen M, Xie T et al (2006) Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 27: 260-266
41. Szabo V, Kreienkamp HJ, Rosenberg T et al (2007) p.Gln200Glu, a putative constitutively active mutant of rod alpha-transducin (GNAT1) in autosomal dominant congenital stationary night blindness. Hum Mutat 28:741-742
42. Naeem MA, Chavali VR, Ali S et al (2012) GNAT1 associated with autosomal recessive congenital stationary night blindness. Invest Ophthalmol Vis Sci 53:1353-1361
43. Ouechtati F, Merdassi A, Bouyacoub Y et al (2011) Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identifi cation of a new nonsense mutation in GNAT2 gene. J Hum Genet 56: 22-28
44. Rosenberg T, Baumann B, Kohl S et al (2004) Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations. Invest Ophthalmol Vis Sci 45: 4256-4262
45. Goldlust IS, Hermetz KE, Catalano LM et al (2013) Mouse model implicates GNB3 duplication in a childhood obesity syndrome. Proc Natl Acad Sci U S A 110:14990-14994
46. Klenke S, Kussmann M, Siffert W (2011) The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics 21:594-606
47. Tang H, Wei P, Duell EJ et al (2014) Genesenvironment interactions in obesity-and diabetes-associated pancreatic cancer: a GWAS data analysis. Cancer Epidemiol Biomarkers Prev 23(1):98-106
48. Elli FM, deSanctis L, Ceoloni B et al (2013) Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. Hum Mutat 34:411-416
49. Iiri T, Herzmark P, Nakamoto JM et al (1994) Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature 371:164-168
50. Thompson MD, Percy ME, Burnham WM et al (2008) G Protein-coupled receptors disrupted in human genetic disease. Methods Mol Biol 448:109-138
51. Wensel T (1999) Introduction to cellular signal transduction. In: Sitaramayya A (ed) Heterotrimeric G-proteins: structure, regulation and signaling mechanisms. Introductory signal transduction. Birkhanser, Boston, MA, pp 29-46
52. Spiegel AM (1996) Defects in G proteincoupled signal transduction in human disease. Annu Rev Physiol 58:143-170
53. Sunahara RK, Dessauer CW et al (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480
54. Tang CM, Insel PA (2005) Genetic variation in G-protein-coupled receptors—consequences for G-protein-coupled receptors as drug targets. Expert Opin Ther Targets 9:1247-1265
55. Rebois RV, Hebert TE (2003) Protein complexes involved in heptahelical receptormediated signal transduction. Receptors Channels 9:169-194
56. Chidiac P (1998) Rethinking receptor-G protein-effector interactions. Biochem Pharmacol 55:549-556
57. Logothetis DE, Kurachi Y, Galper J et al (1987) The beta gamma subunits of GTP-binding proteins activate the muscarinic K + channel in heart. Nature 325:321-326
58. Smrcka AV (2008) G protein βγ subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci 65:2191-2214
59. Witherow DS, Slepak VZ (2003) A novel kind of G protein heterodimer: the G beta5-RGS complex. Receptors Channels 9:205-212
60. Premont RT, Inglese J, Lefkowitz RJ (1995) Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9:175-182
61. Ray K, Kunsch C, Bonner LM et al (1995) Isolation of cDNA clones encoding eight different human G protein gamma subunits, including three novel forms designated the gamma 4, gamma 10, and gamma 11 subunits. J Biol Chem 270:21765-21771
62. Hepler JR, Gilman AG (1992) G-proteins. Trends Biochem Sci 17:383-387
63. Siffert W, Rosskopf D, Siffert G et al (1998) Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18:45-48
64. Sun A, Ge J, Siffert W, Frey UH (2005) Quantifi cation of allele-specifi c G-protein beta3 subunit mRNA transcripts in different human cells and tissues by Pyrosequencing. Eur J Hum Genet 13:361-369
65. Siffert W (2001) Molecular genetics of G proteins and atherosclerosis risk. Basic Res Cardiol 96:606-611
66. Mitchell A, Pace M, Nurnberger J et al (2005) Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein beta3 subunit gene (GNB3). Clin Pharmacol Ther 77:495-502
67. Matsunaga T, Nagasumi K, Yamamura T et al (2005) Association of C825T polymorphism of G protein beta3 subunit with the autonomic nervous system in young healthy Japanese individuals. Am J Hypertens 18: 523-529
68. Kiani JG, Saeed M, Parvez SH et al (2005) Association of G-protein beta-3 subunit gene (GNB3) T825 allele with type II diabetes. Neuro Endocrinol Lett 26:87-88
69. Fernandez-Real JM, Penarroja G, Richart C et al (2003) G protein beta3 gene variant, vascular function, and insulin sensitivity in type 2 diabetes. Hypertension 41:124-129
70. Terra SG, McGorray SP, Wu R et al (2005) Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes (Lond) 29:746-754
71. Andersen G, Overgaard J, Albrechtsen A et al (2006) Studies of the association of the GNB3 825C > T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia 49:75-82
72. Meirhaeghe A, Cottel D, Amouyel P et al (2005) Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab 86: 293-299
73. Bullido MJ, Ramos MC, Ruiz-Gomez A et al (2004) Polymorphism in genes involved in adrenergic signaling associated with Alzheimer’s. Neurobiol Aging 25:853-859
74. Klintschar M, Stiller D, Schwaiger P et al (2005) DNA polymorphisms in the tyrosine hydroxylase and GNB3 genes: association with unexpected death from acute myocardial infarction and increased heart weight. Forensic Sci Int 153:142-146
75. Eisenhardt A, Siffert W, Rosskopf D et al (2005) Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer. World J Urol 23:279-286
76. Sheu SY, Gorges R, Ensinger C et al (2005) Different genotype distribution of the GNB3 C825T polymorphism of the G protein beta3 subunit in adenomas and differentiated thyroid carcinomas of follicular cell origin. J Pathol 207:430-435
77. Sarrazin C, Berg T, Weich V et al (2005) GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. J Hepatol 43:388-393
78. Lee HJ, Cha JH, Ham BJ et al (2004) Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 4: 29-33
79. Muller DJ, De Luca V, Sicard T et al (2005) Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 15:525-531
80. Schelleman H, Stricker BH, Verschuren WM et al (2006) Interactions between fi ve candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 6: 22-26
81. Muller S, Lohse MJ (1995) The role of G-protein beta gamma subunits in signal transduction. Biochem Soc Trans 23:141-148
82. Tang WJ, Gilman AG (1991) Type-specifi c regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254: 1500-1503
83. Ueda N, Iniguez-Lluhi JA, Lee E et al (1994) G protein beta gamma subunits. Simplifi ed purifi cation and properties of novel isoforms. J Biol Chem 269:4388-4395
84. Boyer JL, Graber SG, Waldo GL et al (1994) Selective activation of phospholipase C by recombinant G-protein alpha-and beta gamma-subunits. J Biol Chem 269: 2814-2819
85. Carty DJ, Padrell E, Codina J et al (1990) Distinct guanine nucleotide binding and release properties of the three Gi proteins. J Biol Chem 265:6268-6273
86. Bourne HR, Stryer L (1992) G proteins. The target sets the tempo. Nature 358:541-543
87. Abramow-Newerly M, Roy AA, Nunn C et al (2006) RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal 18:579-591
88. Hubbard KB, Hepler JR (2006) Cell signalling diversity of the Gqα family of heterotrimeric G proteins. Cell Signal 18:135-150
89. Jiang LI, Collins J, Davis R et al (2008) Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII. J Biol Chem 283:23429-23439
90. Tanabe S, Kreutz B, Suzuki N et al (2004) Regulation of RGS-RhoGEFs by G alpha 12 and G alpha 13 proteins. Methods Enzymol 390:285-294
91. Milligan G, Kostenis E (2006) Heterotrimeric G-proteins: a short history. Br J Pharmacol 147:S46-S55
92. Weinstein LS, Xie T, Qasem A et al (2010) The role of GNAS and other imprinted genes in the development of obesity. Int J Obes (Lond) 34:6-17
93. Shenker A, Weinstein LS, Sweet DE et al (1994) An activating Gs alpha mutation is present in fi brous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 79:750-755
94. Fragoso MC, Domenice S, Latronico AC et al (2003) Cushing’s syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 88:2147-2151
95. Roman R, Johnson MC, Codner E et al (2004) Activating GNAS1 gene mutations in patients with premature thelarche. J Pediatr 145:218-222
96. Spiegel AM (1990) Albright’s hereditary osteodystrophy and defective G proteins. N Engl J Med 322:1461-1462
97. Weinstein LS, Yu S, Warner DR et al (2001) Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675-705
98. Bastepe M, Weinstein LS, Ogata N et al (2004) Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo . Proc Natl Acad Sci U S A 101:14794-14799
99. Sakamoto A, Chen M, Kobayashi T et al (2005) Chondrocyte-specifi c knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J Bone Miner Res 20:663-671
100. Germain-Lee EL, Groman J, Crane JL, Jan de Beur SM, Levine MA (2003) Growth hormone defi ciency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 88:4059-4069
101. Mantovani G, Maghnie M, Weber G et al (2003) Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 88:4070-4074
102. Yu S, Yu D, Lee E et al (1998) Variable and tissue-specifi c hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specifi c imprinting of the gsalpha gene. Proc Natl Acad Sci U S A 95:8715-8720
103. Hayward BE, Barlier A, Korbonits M et al (2001) Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 107:R31-R36
104. Mantovani G, Ballare E, Giammona E et al (2002) The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 87:4736-4740
105. Germain-Lee EL, Ding CL, Deng Z et al (2002) Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 296:67-72
106. Liu J, Erlichman B, Weinstein LS (2003) The stimulatory G protein alpha-subunit Gs alpha is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 88:4336-4341
107. Bastepe M, Frohlich LF, Linglart A et al (2005) Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 37:25-27
108. Bastepe M, Lane AH, Juppner H (2001) Paternal uniparental isodisomy of chromosome 20q—and the resulting changes in GNAS1 methylation—as a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 68:1283-1289
109. Wu WI, Schwindinger WF, Aparicio LF et al (2001) Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s). A cause of pseudohypoparathyroidism type Ib. J Biol Chem 276:165-171
110. Cismowski MJ (2006) Non-receptor activators of heterotrimeric G-protein signaling (AGS proteins). Semin Cell Dev Biol 17:334-344
111. Sato M, Cismowski MJ, Toyota E et al (2006) Identifi cation of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gbetagamma. Proc Natl Acad Sci U S A 103:797-802
112. De Vries L, Zheng B, Fischer T et al (2000) The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 40:235-271
113. Hepler JR (2003) RGS protein and G protein interactions: a little help from their friends. Mol Pharmacol 64:547-549
114. Roy AA, Lemberg KE, Chidiac P (2003) Recruitment of RGS2 and RGS4 to the plasma membrane by G proteins and receptors refl ects functional interactions. Mol Pharmacol 64:587-593
115. Riddle EL, Rana BK, Murthy KK et al (2006) Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives. Hypertension 47:415-420
116. Chidiac P, Roy AA (2003) Activity, regulation, and intracellular localization of RGS proteins. Receptors Channels 9:135-147
117. Bernstein LS, Ramineni S, Hague C et al (2004) RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate G(q/11 alpha) signaling. J Biol Chem 279:21248-21256
118. Blumer JB, Smrcka AV, Lanier SM (2007) Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling. Pharmacol Ther 113:488-506
119. Zhao P, Cladman W, Van Tol HH et al (2013) Fine-tuning of GPCR signals by intracellular G protein modulators. Prog Mol Biol Transl Sci 115:421-453
120. Xie Z, Liu D, Liu S et al (2011) Identifi cation of a cAMP-response element in the regulator of G-protein signaling-2 (RGS2) promoter as a key cis-regulatory element for RGS2 transcriptional regulation by angiotensin II in cultured vascular smooth muscles. J Biol Chem 286:44646-44658
121. Chidiac P, Ross EM (1999) Phospholipase C-beta1 directly accelerates GTP hydrolysis by Galphaq and acceleration is inhibited by Gbeta gamma subunits. J Biol Chem 274:19639-19643
122. Siehler S (2009) Regulation of RhoGEF proteins by G12/13-coupled receptors. Br J Pharmacol 158:41-49
123. Berman DM, Gilman AG (1998) Mammalian RGS proteins: barbarians at the gate. J Biol Chem 273:1269-1272
124. Tsang S, Woo AY, Zhu W et al (2010) Deregulation of RGS2 in cardiovascular diseases. Front Biosci (Schol Ed) 2:547-557
125. Manzur M, Ganss R (2009) Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med 19:26-30
126. Gu S, Cifelli C, Wang S et al (2009) RGS proteins: identifying new GAPs in the understanding of blood pressure regulation and cardiovascular function. Clin Sci (Lond) 116:391-399
127. Doggrell SA (2004) Is RGS-2 a new drug development target in cardiovascular disease? Expert Opin Ther Targets 8:355-358
128. Heximer SP, Knutsen RH, Sun X et al (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-defi cient mice. J Clin Invest 111:1259
129. Sun X, Kaltenbronn KM, Steinberg TH et al (2005) RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling. Mol Pharmacol 67:631-639
130. Tiret L, Bonnardeaux A, Poirier O et al (1994) Synergistic effects of angiotensinconverting enzyme and angiotensin-II type-1 receptor gene polymorphisms on risk of myocardial-infarction. Lancet 344:910-913
131. Takami S, Katsuya T, Rakugi H et al (1998) Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension. Am J Hypertens 11:316-321
132. Calo LA, Pagnin E, Davis PA et al (2004) Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter’s/Gitelman’s syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 89:4153-4157
133. Gao Y, Portugal AD, Negash S et al (2007) Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia. Am J Physiol Lung Cell Mol Physiol 292:L678-L684
134. Riddle EL, Schwartzman RA, Bond M et al (2005) Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ Res 96:401-411
135. Semplicini A, Lenzini L, Sartori M et al (2006) Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 24:1115-1124
136. Salomon Y, Londos C, Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548
137. Lamey M, Thompson M, Varghese G et al (2002) Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D-1 receptor. J Biol Chem 277:9415-9421
138. Krupnick JG, Benovic JL (1998) The role of receptor kinases and arrestins in G proteincoupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319
139. Zhao X, Palczewski K, Ohguro H (1995) Mechanism of rhodopsin phosphorylation. Biophys Chem 56:183-188
140. Jiang D, Sibley DR (1999) Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. Mol Pharmacol 56:675-683
141. Hausdorff WP, Bouvier M, O’Dowd BF et al (1989) Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem 264:12657-12665
142. Lohse MJ, Benovic JL, Caron MG et al (1990) Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specifi c inhibitors. J Biol Chem 265:3202-3211
143. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179:171-188
144. Lewis MM, Watts VJ, Lawler CP et al (1998) Homologous desensitization of the D1A dopamine receptor: effi cacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286:345-353
145. Shih M, Malbon CC (1994) Oligodeoxynucleotides antisense to mRNA encoding protein kinase A, protein kinase C, and beta-adrenergic receptor kinase reveal distinctive cell-type-specifi c roles in agonistinduced desensitization. Proc Natl Acad Sci U S A 91:12193-12197
146. Roth NS, Campbell PT, Caron MG et al (1991) Comparative rates of desensitization of beta-adrenergic receptors by the betaadrenergic receptor kinase and the cyclic AMP-dependent protein kinase. Proc Natl Acad Sci U S A 88:6201-6204
147. Eason MG, Moreira SP, Liggett SB (1995) Four consecutive serines in the third intracellular loop are the sites for beta-adrenergic receptor kinase-mediated phosphorylation and desensitization of the alpha 2A-adrenergic receptor. J Biol Chem 270:4681-4688
148. Diviani D, Lattion AL, Cotecchia S (1997) Characterization of the phosphorylation sites involved in G protein-coupled receptor kinase and protein kinase C-mediated desensitization of the alpha1B-adrenergic receptor. J Biol Chem 272:28712-28719
149. Maestes DC, Potter RM, Prossnitz ER (1999) Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor. J Biol Chem 274:29791-29795
150. Tsuga H, Kameyama K, Haga T et al (1998) Internalization and down-regulation of human muscarinic acetylcholine receptor m2 subtypes. Role of third intracellular m2 loop and G protein-coupled receptor kinase 2. J Biol Chem 273:5323-5330
151. Pals-Rylaarsdam R, Hosey MM (1997) Two homologous phosphorylation domains differentially contribute to desensitization and internalization of the m2 muscarinic acetyl-choline receptor. J Biol Chem 272:14152-14158
152. Tiberi M, Nash SR, Bertrand L et al (1996) Differential regulation of dopamine D1 receptor responsiveness by various G proteincoupled receptor kinases. J Biol Chem 271:3771-3778
153. Bouvier M, Hausdorff WP, de Blasi A et al (1988) Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature 333:370-373
154. Hausdorff WP, Campbell PT, Ostrowski J et al (1991) A small region of the betaadrenergic receptor is selectively involved in its rapid regulation. Proc Natl Acad Sci U S A 88:2979-2983
155. Fredericks ZL, Pitcher JA, Lefkowitz RJ (1996) Identifi cation of the G proteincoupled receptor kinase phosphorylation sites in the human beta2-adrenergic receptor. J Biol Chem 271:13796-13803
156. Seibold A, January BG, Friedman J et al (1998) Desensitization of beta2-adrenergic receptors with mutations of the proposed G protein-coupled receptor kinase phosphorylation sites. J Biol Chem 273:7637-7642
157. Pak Y, O’Dowd BF, George SR (1997) Agonist-induced desensitization of the mu opioid receptor is determined by threonine 394 preceded by acidic amino acids in the COOH-terminal tail. J Biol Chem 272:24961-24965
158. Guo J, Wu Y, Zhang W et al (2000) Identifi cation of G protein-coupled receptor kinase 2 phosphorylation sites responsible for agonist-stimulated delta-opioid receptor phosphorylation. Mol Pharmacol 58:1050-1056
159. Palmer TM, Benovic JL, Stiles GL (1995) Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. J Biol Chem 270:29607-29613
160. Palmer TM, Stiles GL (1997) Identifi cation of an A2a adenosine receptor domain specifi-cally responsible for mediating short-term desensitization. Biochemistry 36:832-838
161. Palmer TM, Stiles GL (2000) Identifi cation of threonine residues controlling the agonistdependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol Pharmacol 57:539-545
162. Vargas GA, von Zastrow M (2004) Identifi cation of a novel endocytic recycling signal in the D1 dopamine receptor. J Biol Chem 279:37461-37469
163. Ohguro H, Van Hooser JP, Milam AH et al (1995) Rhodopsin phosphorylation and dephosphorylation in vivo. J Biol Chem 270:14259-14262
164. Liggett SB (2011) Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci Signal 4(185):pe36. doi: 10.1126?scisignal.2002331
165. Kim OJ, Gardner BR, Williams DB et al (2004) The role of phosphorylation in D1 Dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J Biol Chem 279:7999-8010
166. Ferguson SS, Barak LS, Zhang J et al (1996) G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095-1110
167. Ferguson SS, Downey WE, Colapietro AM et al (1996) Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-366
168. Faussner A, Proud D, Towns M et al (1998) Infl uence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J Biol Chem 273:2617-2623
169. Tan CM, Brady AE, Nickols HH et al (2004) Membrane traffi cking of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 44:559-609
170. Pals-Rylaarsdam R, Xu Y, Witt-Enderby P et al (1995) Desensitization and internalization of the m2 muscarinic acetylcholine receptor are directed by independent mechanisms. J Biol Chem 270:29004-29011
171. Seibold A, Williams B, Huang ZF et al (2000) Localization of the sites mediating desensitization of the beta(2)-adrenergic receptor by the GRK pathway. Mol Pharmacol 58:1162-1173
172. Pak Y, O’Dowd BF, Wang JB et al (1999) Agonist-induced G protein-dependent and-independent down-regulation of the mu opioid receptor. The receptor is a direct substrate for protein-tyrosine kinase. J Biol Chem 274:27610-27616
173. Hasbi A, Allouche S, Sichel F et al (2000) Internalization and recycling of delta-opioid receptor are dependent on a phosphorylationdephosphorylation mechanism. J Biol Chem 293:237-247
174. Mathuru AL, Mundell SL, Benovic JL et al (2001) Rapid agonist-induced desensitization and internalization of the a2b adenosine receptor is mediated by a serine residue close to the COOH terminus. J Biochem 276:30199-30207
175. Holtmann MH, Roettger BF, Pinon DI et al (1996) Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem 271:23566-23571
176. Moffett S, Rousseau G, Lagace M et al (2001) The palmitoylation state of the beta2-adrenergic receptor regulates the synergistic action of cyclic AMP-dependent protein kinase and beta2-adrenergic receptor kinase involved in its phosphorylation and desensitization. J Neurochem 76:269-279
177. Lee KB, Ptasienski JA, Pals-Rylaarsdam R et al (2000) Arrestin binding to the M(2) muscarinic acetylcholine receptor is precluded by an inhibitory element in the third intracellular loop of the receptor. J Biol Chem 275:9284-9289
178. Goodman OB Jr, Krupnick JG, Santini F et al (1996) Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383:447-450
179. Hinshaw JE, Schmid SL (1995) Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding. Nature 374:190-192
180. Takei K, McPherson PS, Schmid SL et al (1995) Tubular membrane invaginations coated by dynamin rings are induced by GTPgamma S in nerve terminals. Nature 374: 186-190
181. Schmid SL (1992) The mechanism of receptor-mediated endocytosis—more questions than answers. Bioessays 14:589-596
182. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677-18680
183. Freedman NJ, Lefkowitz RJ (1996) Desensitization of G protein-coupled receptors. Recent Prog Horm Res 51:319-351
184. Pitcher JA, Freedman NJ, Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653-692
185. Krueger KM, Daaka Y, Pitcher JA et al (1997) The role of sequestration in G proteincoupled receptor resensitization. Regulation of beta2-adrenergic receptor dephosphorylation by vesicular acidifi cation. J Biol Chem 272:5-8
186. Pippig S, Andexinger S, Lohse MJ (1995) Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization. Mol Pharmacol 47:666-676
187. Koenig JA, Edwardson JM (1997) Endocytosis and recycling of G proteincoupled receptors. Trends Pharmacol Sci 18:276-287
188. Barak LS, Tiberi M, Freedman NJ et al (1994) A highly conserved tyrosine residue in G protein-coupled receptors is required for agonist-mediated beta 2-adrenergic receptor sequestration. J Biol Chem 269:2790-2795
189. Gabilondo AM, Hegler J, Krasel C et al (1997) A dileucine motif in the C terminus of the beta2-adrenergic receptor is involved in receptor internalization. Proc Natl Acad Sci U S A 94:12285-12290
190. Preisser L, Ancellin N, Michaelis L et al (1999) Role of the carboxyl-terminal region, di-leucine motif and cysteine residues in signalling and internalization of vasopressin V1a receptor. FEBS Lett 460:303-308
191. Benya RV, Fathi Z, Battey JF et al (1993) Serines and threonines in the gastrin-releasing peptide receptor carboxyl terminus mediate internalization. J Biol Chem 268: 20285-20290
192. Roth A, Kreienkamp HJ, Meyerhof W et al (1997) Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem 272:23769-23774
193. Pizard A, Blaukat A, Muller-Esterl W et al (1999) Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 274:12738-12747
194. Kennelly PJ, Krebs EG (1991) Consensus sequences as substrate specifi city determinants for protein kinases and protein phosphatases. J Biol Chem 266:15555-15558
195. Onorato JJ, Palczewski K, Regan JW et al (1991) Role of acidic amino acids in peptide substrates of the beta-adrenergic receptor kinase and rhodopsin kinase. Biochemistry 30:5118-5125
196. Inglese J, Freedman NJ, Koch WJ et al (1993) Structure and mechanism of the G proteincoupled receptor kinases. J Biol Chem 268:23735-23738
197. Oppermann M, Diverse-Pierluissi M, Drazner MH et al (1996) Monoclonal antibodies reveal receptor specifi city among G-proteincoupled receptor kinases. Proc Natl Acad Sci U S A 93:7649-7654
198. Chen CK, Zhang K, Church-Kopish J et al (2001) Characterization of human GRK7 as a potential cone opsin kinase. Mol Vis 7:305-313
199. Min L, Ascoli M (2000) Effect of activating and inactivating mutations on the phosphorylation and traffi cking of the human lutropin?choriogonadotropin receptor. Mol Endocrinol 14:1797-1810
200. Loudon RP, Benovic JL (1994) Expression, purifi cation, and characterization of the G protein-coupled receptor kinase GRK6. J Biol Chem 269:22691-22697
201. Rankin ML, Marinec PS, Cabrera DM et al (2006) The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4. Mol Pharmacol 69: 759-769
202. Yu P, Asico LD, Luo Y et al (2006) D1 Dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension. Kidney Int 70:1072-1079
203. Felder RA, Jose PA (2006) Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol 2:637-650
204. Dryja TP (2000) Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture. Am J Ophthalmol 130:547-563
205. Sandberg MA, Weigel-DiFranco C, Rosner B et al (1996) The relationship between visual fi eld size and electroretinogram amplitude in retinitis pigmentosa. Invest Ophthalmol Vis Sci 37:1693-1698
206. Cideciyan AV, Zhao X, Nielsen L et al (1998) Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. Proc Natl Acad Sci U S A 95:328-333
207. Shenker A (1995) G protein-coupled receptor structure and function: the impact of disease-causing mutations. Baillieres Clin Endocrinol Metab 9:427-451